Another name, a new future
A new mid-size, legally independent company will be set-up from the second quarter of 2006 by LANXESS.
A new mid-size, legally independent company will be set-up from the second quarter of 2006 by LANXESS. The company's fine chemical business unit will have a new name, new alignment and a new business model.
The separated company will be called Saltigo and will offer expertise in custom manufacturing to the global market. It will be a wholly owned subsidiary and will start with a capital investment from the parent company of €50 million up to the end of 2007, which may be doubled by 2010.
Sustainable improvement in commercial efficiency is an important objective for the company to close the gap with the competition. An agreement with the works council to lower the amount of employees by 500 has been reached, and to aid the mid-size company's start and create a favourable framework, unprofitable facilities will be closed.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
